Vaccine innovation model: A technology transfer perspective in pandemic contexts

This work identifies the innovations that made it possible for the Bio-Manguinhos/Fiocruz Immunobiological Technology Institute to engage in the entire production of the Oxford/AstraZeneca vaccine (ChAdOx1 nCov-19) in Brazil, just 1.8 years after the COVID-19 pandemic was declared. The results were...

Descripción completa

Detalles Bibliográficos
Autores principales: Medeiros, Maurício Z., Soares, Priscila F., Fialho, Beatriz C., Gauss, Leandro, Piran, Fábio S., Lacerda, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236274/
https://www.ncbi.nlm.nih.gov/pubmed/35773123
http://dx.doi.org/10.1016/j.vaccine.2022.06.054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236274/
https://www.ncbi.nlm.nih.gov/pubmed/35773123
http://dx.doi.org/10.1016/j.vaccine.2022.06.054

Ejemplares similares